iSGTW - International Science Grid This Week
iSGTW - International Science Grid This Week

Home > iSGTW 18 June 2008 > iSGTW Feature - National Grid tackles HIV

Feature - Tackling HIV via the grid

The expulsion of saquinavir from particular HIV-1 protease mutant.
Image courtesy of P V Coveney.

The United Kingdom’s National Grid Service (NGS) played a key role in helping scientists simulate the efficacy of an HIV drug in blocking a key protein used by the virus. The experiment by Peter Coveney, Ileana Stoica and Kashif Sadiq from the Department of Chemistry at University College London, performed a sequence of simulation steps across the UK’s NGS and America’s TeraGrid.

The team ran a large number of simulations to predict how strongly the drug saquinavir would bind to three resistant mutants of HIV-1 protease and its original strain—or “wild-type” protease (one of the proteins produced by the virus to propagate itself). Saquinavir is a known inhibitor of HIV-1 protease as it blocks the maturation step of the HIV life cycle.

Several drugs have the ability to inhibit HIV-1 protease but doctors currently have no direct way of matching the right drug to the right strain, as the virus rapidly mutates in each patient to create a unique version. Even though doctors do have the ability to obtain a patient’s protein sequences through methods such as genotypic assays, in the end, they are still forced to prescribe a “cocktail” containing a variety of drugs, choosing their ingredients by making use of historical data and various rules of thumb obtained from past experience. They then typically work through something of a  trial-and-error process to see which drug works best, by analyzing the patient’s immune response.

An artist’s rendition of blood cells—one of the bodily fluids involved in speading the virus that causes AIDS.  Image copyright of Jusben and MorgueFile. Used with permission.  

What grids could do

A long-held goal of physicians is to replace this “shotgun” strategy with individualized, patient specific treatments custom-tailored to each person’s unique genotype.

Professor Peter Coveney said: “This study represents a first step towards the ultimate goal of ‘on-demand’ medical computing, where doctors could one day ‘borrow’ supercomputing time from the national grid to make critical decisions on life-saving treatments.”

“For example, for an HIV patient, a doctor could perform an assay to establish the patient’s genotype and then rank the available drugs’ efficacy against that patient’s profile based upon a rapid set of large-scale simulations, enabling the doctor to tailor the treatment accordingly.”

Coveney admits that there are questions about the application, such as how many computing resources could be devoted to helping individual patients, and at what price. He said, “At present, such simulations—requiring a substantial amount of computing power—might prove costly for the (UK’s) National Health Service, but technological advances and those in the economics of computing would bring costs down.”

Gillian Sinclair, National Grid Service


 iSGTW 22 December 2010

Feature – Army of Women allies with CaBIG for online longitudinal studies

Special Announcement - iSGTW on Holiday

Video of the Week - Learn about LiDAR


NeHC launches social media

PRACE announces third Tier-0 machine

iRODS 2011 User Group Meeting

Jobs in distributed computing


Enter your email address to subscribe to iSGTW.


 iSGTW Blog Watch

Keep up with the grid’s blogosphere

 Mark your calendar

December 2010

13-18, AGU Fall Meeting

14-16, UCC 2010

17, ICETI 2011 and ICSIT 2011

24, Abstract Submission deadline, EGI User Forum


January 2011

11, HPCS 2011 Submission Deadline

11, SPCloud 2011

22, ALENEX11

30 Jan – 3 Feb, ESCC/Internet2


February 2011

1 - 4, GlobusWorld '11

2, Lift 11

15 - 16, Cloudscape III

More calendar items . . .


FooterINFSOMEuropean CommissionDepartment of EnergyNational¬†Science¬†Foundation RSSHeadlines | Site Map